Drugs / MG005
last change Jul 2020 re-read 2 minutes ago

MG005

Developed for
cancer
Investigated by
Metagone Biotech Inc.

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03406364 Jun 2018 → Jan 2020 cancer Metagone Biotech Inc. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MG005 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03406364